MCID: MGR003
MIFTS: 43

Migraine with Aura malady

Category: Neuronal diseases

Aliases & Classifications for Migraine with Aura

About this section

Aliases & Descriptions for Migraine with Aura:

Name: Migraine with Aura 10 12 36 65
Migraine with Typical Aura 65
 
Classic Migraine 10

Classifications:



External Ids:

Disease Ontology10 DOID:10024
SNOMED-CT59 155047002, 4473006
ICD9CM29 346.0
MeSH36 D020325
UMLS65 C0154723, C1735856

Summaries for Migraine with Aura

About this section
Disease Ontology:10 A migraine characterized by migraine headache which is preceded or accompanied by a transient focal neurological phenomenon.

MalaCards based summary: Migraine with Aura, also known as migraine with typical aura, is related to colitis and generalized epilepsy with febrile seizures plus. An important gene associated with Migraine with Aura is KCNK18 (Potassium Two Pore Domain Channel Subfamily K Member 18), and among its related pathways are Serotonin Receptor 2 and ELK-SRF/GATA4 signaling and Transcription_Transcription factor Tubby signaling pathways. Affiliated tissues include brain, pituitary and endothelial, and related mouse phenotypes are normal and endocrine/exocrine gland.

Related Diseases for Migraine with Aura

About this section

Graphical network of the top 20 diseases related to Migraine with Aura:



Diseases related to migraine with aura

Symptoms for Migraine with Aura

About this section

Drugs & Therapeutics for Migraine with Aura

About this section

Drugs for Migraine with Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 168)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
RizatriptanapprovedPhase 4, Phase 335145202-66-05078
Synonyms:
144034-80-0
AC-1712
AC1L1JK9
BIDD:GT0361
C093622
CHEBI:48273
CHEMBL905
CID5078
D08485
DB00953
I06-2272
L000812
LS-83053
MK 462 Free Base
MK 462 free base
Maxalt
Maxalt-mlt
MolPort-003-666-600
 
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine
N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine
N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine
N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine
N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
NCGC00095899-01
Risatriptan
Rizatriptan
Rizatriptan (INN)
Rizatriptan Benzoate
Rizatriptan [INN:BAN]
Rizatriptan benzoat
Rizatriptan benzoate
Rizatriptanum
SPECTRUM1505189
TL8000966
UNII-51086HBW8G
rizatriptan
rizatriptanum
2
Eletriptanapproved, investigationalPhase 4, Phase 319143322-58-177993
Synonyms:
(R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole
(R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole
143322-58-1
3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole
3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole
5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
AB1004885
AC-3397
AC1L2U98
AKOS005145842
CHEBI:50922
CHEMBL1510
CID77993
D07887
DB00216
 
Eletriptan
Eletriptan (INN)
Eletriptan [INN:BAN]
Eletriptan hydrobromide
Eletriptanum
LS-186998
LS-187637
MolPort-005-940-717
NCGC00181130-01
Relpax
UK 116044
UK-116044
UK-116044-04
UK116044
UNII-22QOO9B8KI
eletriptanum
3
Metoclopramideapproved, investigationalPhase 4, Phase 3102364-62-54168
Synonyms:
(metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
(metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one
2-Methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide
2-Methoxy-5-chloroprocainamide
2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
2-methoxy-5-chloroprocainamide
2576-84-3 (di-hydrochloride)
364-62-5
4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide
4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide
4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp)
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide)
4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide)
4-amino-5-chloro-2-Methoxy-N-(beta-diethylaminoethyl)benzamide
4-amino-5-chloro-N-(2-(Diethylamino)ethyl)-2-methoxybenzamide
4-amino-5-chloro-N-(2-(Diethylamino)ethyl)-O-anisamide
4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
5-Chloro-2-methoxyprocainamide
54143-57-6 (mono-hydrochloride, mono-hydrate)
7232-21-5 (mono-hydrochloride)
AB00053498
AC1L1HKD
AKOS000280832
ARONIS24307
Apo-Metoclop
BPBio1_000217
BPBio1_001100
BRD-K75641298-001-01-5
BRD-K75641298-003-05-2
BRN 1884366
BSPBio_000197
BSPBio_002027
Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy- (9CI)
Biomol-NT_000082
C07868
C14H22ClN3O2
CAS-7232-21-5
CHEBI:107736
CHEMBL86
CID4168
CLOPRA-"YELLOW"
Cerucal
Clopra
Clopra-Yellow
Clopromate
D00726
DB01233
DEL
DEL 1267
DivK1c_000069
Duraclamid
EINECS 206-662-9
Elieten
Elieten (TN)
Emetid
Emitasol
Emperal
Eucil
Gastrese
Gastro-Timelets
Gastrobid
Gastromax
Gastronerton
Gastrosil
Gastrotablinen
Gastrotem
HMS2089G16
IDI1_000069
Imperan
KBio1_000069
KBio2_002118
KBio2_004686
 
KBio2_007254
KBio3_001527
KBioGR_001307
KBioSS_002118
L001078
LS-20038
Lopac-M-0763
Lopac0_000762
Maxeran
Maxolon
Meclopran
Metaclopramide
Metaclopromide
Metamide
Methochlopramide
Methoclopramide
Metochlopramide
Metoclol
Metoclopramida
Metoclopramida [INN-Spanish]
Metoclopramide
Metoclopramide (JP15/INN)
Metoclopramide Hcl
Metoclopramide Hydrochloride
Metoclopramide Intensol
Metoclopramide Monohydrochloride, Monohydrate
Metoclopramide Omega
Metoclopramide [INN:BAN:JAN]
Metoclopramidum
Metoclopramidum [INN-Latin]
Metocobil
Metonia
Metramid
MolPort-000-883-854
Moriperan
Mygdalon
N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
NCGC00015643-01
NCGC00015643-02
NCGC00015643-03
NCGC00015643-08
NCGC00024440-03
NCGC00024440-04
NCI60_003185
NINDS_000069
Neu-Sensamide
Nu-Metoclopramide
Octamide
Parmid
Paspertin
Peraprin
Plasil
Plasil (pharmaceutical)
Pms-Metoclopramide
Pramidin
Pramiel
Pramin
Prestwick0_000209
Prestwick1_000209
Prestwick2_000209
Prestwick3_000209
Primperan
Reclomide
Reglan
Reliveran
SPBio_001740
SPBio_002118
ST024773
Spectrum2_001720
Spectrum3_000504
Spectrum4_000964
Spectrum5_001449
Spectrum_001638
Terperan
Terperan (TN)
UNII-L4YEB44I46
bmse000779
metoclopramide
o-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)- (8CI)
4
TopiramateapprovedPhase 4, Phase 3, Phase 224097240-79-45284627
Synonyms:
-D-fructopyranose deriv.
.beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI)
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.
97240-79-4
AKOS000424547
BIDD:GT0854
BIDD:PXR0127
BRN 5988957
BSPBio_002306
C052342
C07502
C12H21NO8S
CBChromo1_000352
CHEBI:129573
CHEMBL220492
CID5284627
CPD000466325
Cilag brand of topiramate
D00537
DB00273
Epitoma
Epitomax
HMS1922H06
HMS2051L09
HMS2093D20
HSDB 7531
Janssen brand of topiramate
KS-1122
KW-6485
LS-187392
LS-69764
MLS000759431
MLS001424070
McN 4853
McN-4853
MolPort-001-615-062
MolPort-002-885-869
NCGC00178714-01
Ortho brand of topiramate
 
Qudexy XR
RWJ 17021
RWJ-17021
RWJ-17021-000
S1438_Selleck
SAM001246601
SMR000466325
SPBio_000995
SPECTRUM1505801
STOCK1N-71037
Spectrum2_001128
T0575_SIGMA
TL8006021
TOR
TPM
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Topamac
Topamax
Topamax (TN)
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
Trokendi Xr
UNII-0H73WJJ391
USL-255
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
topiramate
topiramate tablet
topiramatum [Latin]
5
Almotriptanapproved, investigationalPhase 4, Phase 313181183-52-8123606
Synonyms:
1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
154323-57-6
AC1L3WYP
Almogran
Almotriptan
Almotriptan (USAN)
Almotriptan [USAN:INN:BAN]
Axert
BIDD:GT0048
BRD-K67601717-001-02-0
BSPBio_002731
C17H27N3O2S
CHEBI:520985
CHEMBL1505
CID123606
D02824
DB00918
HMS1922L13
I06-0492
KBio2_002408
KBio2_004976
 
KBio2_007544
KBio3_001951
KBioGR_001647
KBioSS_002414
L000846
LAS-31416
LS-173461
MolPort-003-666-604
N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine
N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine
NCGC00095135-01
NCGC00095135-02
NCGC00095135-03
PNU-180638
SPBio_000395
SPECTRUM1505204
Spectrum2_000498
Spectrum3_001006
Spectrum4_001134
Spectrum5_001554
Spectrum_001884
UNII-1O4XL5SN61
6
DiclofenacapprovedPhase 4, Phase 327315307-86-53033
Synonyms:
(2,6-Dichlorophenyl)amino]benzeneacetic acid
15307-81-0 (mono-potassium salt)
15307-86-5
2-((2,6-Dichlorophenyl)amino)benzeneacetic acid
2-(2,6-Dichloroanilino)phenylacetic Acid
2-(2,6-Dichlorophenylamino)phenylacetic acid
2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid
2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID
2-[2-(2,6-Dichlorophenylamino)phenyl]acetic acid
2-[2-(2,6-dichloroanilino)phenyl]acetic acid
2b17
AC1L1F0T
AKOS001579542
Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI)
Allvoran
Apo-Diclo
Assaren
BIDD:GT0380
BPBio1_000516
BRD-K08252256-236-05-6
BRN 2146636
BSPBio_000468
BSPBio_002169
Benfofen
Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)- (9CI)
C01690
CHEBI:47381
CHEMBL139
CID3033
Cambia
Cataflam
D07816
D30801
D3748
DB00586
DIF
Delphimix
Dichlofenac
Dichlofenal
Dichronic
Diclac
Diclo-Phlogont
Diclo-Puren
Diclobenin
Diclofenac
Diclofenac (INN)
Diclofenac Acid
Diclofenac Potassium
Diclofenac Sodium
Diclofenac [INN:BAN]
Diclofenac acid
Diclofenac potassium
Diclofenac sodium
Diclofenaco
Diclofenaco [INN-Spanish]
Diclofenacum
Diclofenacum [INN-Latin]
Diclofenamic acid
Diclomelan
Diclonate P
Diclophenac
Diclord
Dicloreum
Dicloreuma
Dicrofenac
DivK1c_000272
DivK1c_000402
Dolobasan
Duravolten
Dyloject
EINECS 239-348-5
Ecofenac
Effekton
Flector
GP-45,840
HMS2090C10
HMS501E04
HSDB 7234
 
I14-7739
IDI1_000272
IDI1_000402
ISV-205
KBio1_000272
KBio1_000402
KBio2_001410
KBio2_002306
KBio2_003978
KBio2_004874
KBio2_006546
KBio2_007442
KBio3_001389
KBio3_002786
KBioGR_001051
KBioGR_002306
KBioSS_001410
KBioSS_002308
Kriplex
LS-11575
Lopac0_000441
MolPort-000-003-072
N-(2,6-Dichlorop
NCGC00021125-01
NINDS_000272
NINDS_000402
Neriodin
Novapirina
Novo-Difenac
Novo-Difenac SR
Nu-Diclo
Oprea1_011155
Orthofen
Pennsaid
Prestwick0_000594
Prestwick1_000594
Prestwick2_000594
Prestwick3_000594
Primofenac
ProSorb-D
Prophenatin
Rhumalgan
SBB068617
SPBio_001081
SPBio_002687
SR-38
STK984493
Solaraze
Solaraze (TN)
Solaraze T
Spectrum2_000991
Spectrum3_000385
Spectrum4_000506
Spectrum5_000867
Spectrum_000930
Transfenac
Tsudohmin
UNII-144O8QL0L1
UNM000001216103
Valetan
Voldal
Voltaflan
Voltaren
Voltaren Ophtha
Voltaren Ophthalmic
Voltaren Rapide
Voltaren SR
Voltaren ophthalmic
Voltaren-XR
Voltarol
Xenid
Zipsor
Zorvolex
[2-(2,6-Dichloroanilino)phenyl]acetic acid
[o-(2,6-Dichloroanilino)phenyl]acetic acid
cMAP_000014
dichlofenac
diclofenac
henyl)-o-aminophenylacetic acid
{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid
7
NaproxenapprovedPhase 4, Phase 3, Phase 124522204-53-11302, 156391
Synonyms:
(+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(+)-(S)-Naproxen
(+)-2-(6-Methoxy-2-naphthyl)propionic acid
(+)-2-(Methoxy-2-naphthyl)-propionic acid
(+)-2-(Methoxy-2-naphthyl)-propionsaeure
(+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]
(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(+)-Naproxen
(+)NAPROXEN
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
(S)-()-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-()-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-(+)-Naproxen
(S)-2-(6-Methoxy-2-naphthyl)propanoic acid
(S)-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid
(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-Naproxen
2-(6-Methoxy-2-naphthyl)propionic acid
2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI)
22204-53-1
284785_ALDRICH
46482_FLUKA
46482_RIEDEL
65126_FLUKA
AC-1363
AC1L4G3X
AC1Q4ET9
AC1Q4F4H
AC1Q4F4I
ARONIS24306
Acusprain
Aleve
Anaprox
Anax
Anexopen
Apo-Napro-NA
Apo-Naproxen
Apronax
Artagen
Arthrisil
Artrixen
Artroxen
Atiflan
Axer
BIDD:GT0062
BRD-K59197931-001-02-9
BRD-K59197931-236-09-6
BSPBio_002067
Bipronyl
Bonyl
CAS-22204-53-1
CCRIS 5265
CG 3117
CHEBI:7476
CHEMBL154
CID156391
Calosen
Clinosyn
Congex
D-Naproxen
DB08298
DL Naproxen
DL-Naproxen
Danaprox
Daprox
Diocodal
DivK1c_000242
Duk
Dysmenalgit
Dysmenalgit N
EINECS 244-838-7
Ec-Naprosyn
Ec-naprosyn
Equiproxen
Equiproxen (Veterinary)
FT-0082415
Flanax Forte
Flexen
Flexipen
Floginax
Fuxen
Genoxen
HMS1920P13
HMS2089N21
HMS2091H12
HMS500M04
HSDB 3369
Headlon
IDI1_000242
InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
KBio1_000242
KBio2_001457
KBio2_004025
KBio2_006593
KBio3_001567
KBioGR_000597
KBioSS_001457
LS-124738
Laraflex
Lefaine
Leniartil
 
Lopac0_000792
M1021
Methoxypropiocin
MolPort-000-145-960
N8280_SIAL
NAPROXEN
NCGC00016759-01
NCGC00021127-01
NCGC00161591-01
NINDS_000242
NPS
Nafasol
Naixan
Nalyxan
Napflam
Napmel
Naposin
Napratec
Naprelan
Napren
Napren E
Naprius
Naprolag
Naprontag
Naprosin
Naprosyn
Naprosyn LLE
Naprosyn LLE Forte
Naprosyne
Naproxen
Naproxen Kit
Naproxen Sodium
Naproxen [USAN:BAN:INN:JAN]
Naproxen delayed release
Naproxen sodium
Naproxene
Naproxene [INN-French]
Naproxeno
Naproxeno [INN-Spanish]
Naproxenum
Naproxenum [INN-Latin]
Naproxi 250
Naproxi 500
Naproxène
Napxen
Narma
Narocin
Naxen
Naxen F
Naxopren
Naxyn
Naxyn 250
Naxyn 500
Noflam
Novonaprox
Nycopren
Opipramol
Patxen
Prafena
Prestwick0_000791
Prestwick1_000791
Prestwick2_000791
Prestwick_349
Prexan
Priaxen
Pronaxen
Proxen LE
Proxen LLE
RS 3540
RS-3540
Rahsen
Reuxen
Rheumaflex
Roxen
SPBio_000966
SPBio_002861
SPECTRUM1500425
SR-01000075977-3
STOCK1N-50633
Saritilron
Sinartrin
Sinton
Soproxen
Spectrum2_001043
Spectrum3_000514
Spectrum4_000069
Spectrum5_001327
Spectrum_000977
Sutolin
Sutony
TL8003659
Tohexen
Traumox
U-Ritis
UNII-57Y76R9ATQ
UPCMLD-DP001
UPCMLD-DP001:001
Velsay
Veradol
Vinsen
Xenar
d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure
d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]
d-2-(6-Methoxy-2-naphthyl)propionic acid
d-Naproxen
8
Sumatriptanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 197103628-46-25358
Synonyms:
(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
(3-[2-(dimethylamino)Ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide
1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide
103628-46-2
103628-48-4 (succinate)
3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide
3-(2-(dimethylamino)Ethyl)-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
3-[2-(dimethylamino)Ethyl]-N-methylindole-5-methanesulfonamide
AC1L1K6B
Alsuma
Ambap103628-46-2
BIDD:GT0248
BRD-K50938287-001-01-7
BRN 6930870
BSPBio_002304
C07319
C14H21N3O2S
CHEBI:10650
CHEMBL128
CID5358
D00451
DB00669
GR 43175
GR 43175X
GR-43175
 
I06-0076
Imigran
Imigran (TN)
Imigran Recovery
Imitrex
Imitrex (TN)
Imitrex Oral
KS-1116
L000584
LS-83175
MLS001195659
MLS001304742
MolPort-002-885-863
NCGC00095838-01
NCGC00095838-02
NP101
SMR000596517
SPECTRUM1505372
Sumatran
Sumatriptan
Sumatriptan (JAN/USP/INN)
Sumatriptan Succinate
Sumatriptanum
Sumatriptanum [INN-Latin]
Sumatriptán
Sumavel Dosepro
Sumax
UNII-8R78F6L9VO
Zecuity
estradiol
sumatriptan
triptan
9
Propranololapproved, investigationalPhase 4, Phase 3, Phase 2202525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Hemangeol
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal LA
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
 
Innopran XL
Innopran Xl
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
10
KetorolacapprovedPhase 427866635-83-43826
Synonyms:
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-Ketorolac
(+-)-isomer
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC-545
AC1L1GSW
Acular
Acuvail
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
 
I14-2832
Ketoralac
Ketorolac
Ketorolac (INN)
Ketorolac Tromethamine
Ketorolac [INN:BAN]
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
Kétorolac
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
RS 37619
RS-37619
SBB067312
STL018674
Sprix
Toradol (TN)
UNII-YZI5105V0L
ketorolac
rac-Ketorolac
11
DopamineapprovedPhase 4, Phase 3, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
12
Fentanylapproved, illicit, investigationalPhase 4705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
13
MilnacipranapprovedPhase 45892623-85-365833
Synonyms:
( -)-Milnacipran
(+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
(-)-milnacipran
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl
105310-09-6
92623-85-3
AC1L2425
CHEMBL252923
CID65833
D08222
DB04896
F 2207
F-2207
 
F2207
Ixel
LS-178180
Midalcipran
Milnacipran
Milnacipran (INN)
Milnacipran Hydrochloride
Milnacipran [INN]
Milnacipranum
Milnacipranum [Latin]
Milnacipranum [latin]
NCGC00165825-01
Savella
Toledomin
UNII-G56VK1HF36
milnacipran
14Vasoconstrictor AgentsPhase 4, Phase 3, Phase 2, Phase 11303
15Central Nervous System DepressantsPhase 4, Phase 3, Phase 210016
16HormonesPhase 4, Phase 3, Phase 211748
17Psychotropic DrugsPhase 4, Phase 25501
18Contraceptives, OralPhase 4, Phase 23734
19Adrenergic AgentsPhase 4, Phase 3, Phase 24204
20Pharmaceutical SolutionsPhase 47004
21Antihypertensive AgentsPhase 4, Phase 3, Phase 23618
22Anti-Arrhythmia AgentsPhase 4, Phase 3, Phase 22371
23AnalgesicsPhase 4, Phase 3, Phase 2, Phase 19358
24Adrenergic AntagonistsPhase 4, Phase 3, Phase 21253
25Adrenergic beta-AntagonistsPhase 4, Phase 3, Phase 2979
26Vasodilator AgentsPhase 4, Phase 3, Phase 2, Phase 02926
27AnestheticsPhase 4, Phase 37385
28Cyclooxygenase InhibitorsPhase 4, Phase 3, Phase 2, Phase 12225
29Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 15184
30Dopamine AntagonistsPhase 4, Phase 3, Phase 2927
31Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 18496
32Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 3, Phase 2, Phase 13549
33Serotonin AgentsPhase 4, Phase 3, Phase 2, Phase 12668
34AntiemeticsPhase 4, Phase 3, Phase 23213
35Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 18478
36Dopamine D2 Receptor AntagonistsPhase 4, Phase 3258
37Dopamine AgentsPhase 4, Phase 3, Phase 23084
38Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018510
39AnticonvulsantsPhase 4, Phase 3, Phase 22249
40Gastrointestinal AgentsPhase 4, Phase 3, Phase 26401
41Neuroprotective AgentsPhase 4, Phase 3, Phase 2, Phase 01376
42Protective AgentsPhase 4, Phase 3, Phase 2, Phase 05651
43Ketorolac TromethaminePhase 4278
44
SerotoninPhase 4, Phase 3, Phase 2, Phase 1314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
45Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 114795
46Anti-Obesity AgentsPhase 4, Phase 3, Phase 2354
47NorinylPhase 435
48Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combinationPhase 435
49NarcoticsPhase 42709
50Analgesics, OpioidPhase 42304

Interventional clinical trials:

(show top 50)    (show all 137)
idNameStatusNCT IDPhase
1Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency DepartmentCompletedNCT01596166Phase 4
2Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.CompletedNCT00212810Phase 4
3Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of MigraineCompletedNCT00210496Phase 4
4Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year OldsCompletedNCT02287376Phase 4
5A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month PeriodCompletedNCT00792636Phase 4
6A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine HeadacheCompletedNCT00210509Phase 4
7Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.CompletedNCT00753311Phase 4
8Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory DrugsCompletedNCT00634985Phase 4
9An Efficacy and Tolerability Study of Topiramate in Participants With MigraineCompletedNCT01060111Phase 4
10Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and ImitrexCompletedNCT01450995Phase 4
11Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled TrialRecruitingNCT02314351Phase 4
12Chronic Pain Risk Associated With Menstrual Period PainRecruitingNCT02214550Phase 4
13Preventive Treatment of Episodic and Chronic MigraineNot yet recruitingNCT01319825Phase 4
14Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With AuraCompletedNCT00449540Phase 3
15A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of MigraineCompletedNCT00236561Phase 3
16A Study of the Efficacy and Safety of Topiramate in the Prevention of MigraineCompletedNCT00236509Phase 3
17A Study of the Efficacy and Safety of Topiramate in the Prevention of MigraineCompletedNCT00231595Phase 3
18Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose StudyCompletedNCT01859481Phase 3
19Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine HeadacheCompletedNCT00471952Phase 3
20Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With MigraineCompletedNCT00334178Phase 3
21Candesartan Versus Propranolol for Migraine PreventionCompletedNCT00884663Phase 2, Phase 3
22Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for MigraineCompletedNCT01741714Phase 3
23Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine TreatmentCompletedNCT01814189Phase 3
24Dysport® In Migraine Without Aura Prophylaxis : DIMWAP StudyCompletedNCT00258609Phase 3
25A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)CompletedNCT01004263Phase 3
26A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)CompletedNCT00382993Phase 3
27Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)CompletedNCT00442936Phase 3
28TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)CompletedNCT00387881Phase 3
29A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)CompletedNCT00383162Phase 3
30Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack StudyCompletedNCT01986088Phase 3
31Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)CompletedNCT00483704Phase 3
32Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral SumatriptanCompletedNCT01989936Phase 3
33A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in AdolescentsCompletedNCT00210483Phase 3
34An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine AttackCompletedNCT00330850Phase 3
35Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)CompletedNCT00443209Phase 3
36Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)CompletedNCT00432237Phase 3
37TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a MigraineCompletedNCT00385008Phase 3
38Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute MigraineCompletedNCT01462812Phase 3
39Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute MigraineCompletedNCT01978496Phase 3
40Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or WithoutCompletedNCT01667679Phase 3
41Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and PlaceboCompletedNCT01986270Phase 3
42Migraine Study in Adolescent PatientsCompletedNCT00843024Phase 3
43Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of MigrainesCompletedNCT00122278Phase 3
44A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)CompletedNCT00894556Phase 3
45Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic MigraineCompletedNCT00131443Phase 2, Phase 3
46Acupuncture for Migraine ProphylaxisRecruitingNCT01687660Phase 2, Phase 3
47DFN-11 Injection in Episodic Migraine With or Without AuraRecruitingNCT02569853Phase 3
48MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair ImplantActive, not recruitingNCT00283738Phase 2, Phase 3
49A Safety Study of LY2951742 in Participants With Migraine, With or Without AuraActive, not recruitingNCT02614287Phase 3
50The Coherex FlatStent™ EF PFO Migraine RegistryNot yet recruitingNCT01280578Phase 3

Search NIH Clinical Center for Migraine with Aura


Cochrane evidence based reviews: migraine with aura

Genetic Tests for Migraine with Aura

About this section

Anatomical Context for Migraine with Aura

About this section

MalaCards organs/tissues related to Migraine with Aura:

33
Brain, Pituitary, Endothelial, Testes, Breast, Liver, Heart

Animal Models for Migraine with Aura or affiliated genes

About this section

MGI Mouse Phenotypes related to Migraine with Aura:

38 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00028737.8ATP1A2, DBH, DRD2, EDNRA, NOTCH3, SCN1A
2MP:00053797.5DBH, DRD2, EDNRA, HTR2A, INSR, NOTCH3
3MP:00053697.4ATP1A2, DRD2, EDNRA, HTR2A, HTR2C, INSR
4MP:00053907.3DBH, DRD2, EDNRA, HTR2A, MTHFR, NOTCH3
5MP:00107717.2ATP1A2, DBH, DRD2, EDNRA, HTR2C, MTHFR
6MP:00053857.0ATP1A2, DBH, DRD2, EDNRA, INSR, NOTCH3
7MP:00053866.9ATP1A2, DBH, DRD2, HTR2A, HTR2C, INSR
8MP:00053766.6ATP1A2, DBH, DRD2, EDNRA, HTR2C, INSR
9MP:00053786.5DBH, DRD2, EDNRA, HTR2C, INSR, MTHFR
10MP:00107686.2ATP1A2, DBH, DRD2, EDNRA, HTR2C, INSR
11MP:00036316.1ATP1A2, DBH, DRD2, EDNRA, HTR2C, INSR

Publications for Migraine with Aura

About this section

Articles related to Migraine with Aura:

(show top 50)    (show all 332)
idTitleAuthorsYear
1
Cervical and ocular vestibular evoked potentials in Machado-Joseph disease: Functional involvement of otolith pathways. (26365285)
2015
2
Spiradenoma and cylindroma originate from the hair follicle bulge and not from the eccrine sweat gland: an immunohistochemical study with CD200 and other stem cell markers. (25354097)
2014
3
Pneumatic stenting for tracheobronchomalacia. (24739682)
2014
4
Posttonsillectomy hemorrhage in children with von Willebrand disease or hemophilia. (23657425)
2013
5
Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury. (23981724)
2013
6
Increase of oxidative stress by a novel PINK1 mutation, P209A. (23261939)
2013
7
Progeria: pathogenesis and oral manifestation--a review. (22971867)
2012
8
Analysis of osteoprotegerin (OPG) gene polymorphism in Iranian patients with chronic periodontitis and peri-implantitis. A cross-sectional study. (23304691)
2012
9
Lip cancer in renal transplant patients. (21112239)
2011
10
Human herpesvirus 8 in corneal endotheliitis resulting in graft failure after penetrating keratoplasty refractory to allograft rejection therapy. (22159687)
2011
11
Asymptomatic small fiber neuropathy in diabetes mellitus: investigations with intraepidermal nerve fiber density, quantitative sensory testing and laser-evoked potentials. (21472496)
2011
12
The signaling pathway leading to extracellular signal-regulated kinase 5 (ERK5) activation via G-proteins and ERK5-dependent neurotrophic effects. (19858097)
2010
13
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. (20031199)
2010
14
A Second Case of Sunitinib-associated Pyoderma Gangrenosum. (20877540)
2010
15
G protein-coupled receptor 30: estrogen receptor or collaborator? (19307418)
2009
16
SR protein family members display diverse activities in the formation of nascent and mature mRNPs in vivo. (19394295)
2009
17
Contribution of PTEN large rearrangements in Cowden disease: a multiplex amplifiable probe hybridisation (MAPH) screening approach. (18456716)
2008
18
A case of huge colon carcinoma and right renal angiomyolipoma accompanied by proximal deep venous thrombosis, pulmonary embolism and tumor thrombus in the renal vein. (18845524)
2008
19
The human vaginal bacterial biota and bacterial vaginosis. (19282975)
2008
20
Differential effects of interleukin-1 alpha and beta on interleukin-6 and chemokine synthesis in neurones. (18434191)
2008
21
Feeding and insulin increase leptin translation. Importance of the leptin mRNA untranslated regions. (17085442)
2007
22
Roles of PKC, PI3K and JNK in multiple transduction of CCN2/CTGF signals in chondrocytes. (16431170)
2006
23
In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes. (16778109)
2006
24
Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. (16520412)
2006
25
Novel missense mutation in the CASR gene in a Chinese family with familial hypocalciuric hypercalcemia. (15963484)
2005
26
Lipopolysaccharide-binding protein is produced in the epididymis and associated with spermatozoa and prostasomes. (15949560)
2005
27
Clinical report of congenital lymphatic malformations and partial gigantism of the hands associated with a heterogeneous karyotype. (15472995)
2005
28
The expressions of survivin and VEGF in squamous cell carcinoma of larynx and the correlation between the two marks]. (16375117)
2005
29
9alpha-Fluorohydrocortisone therapy in aldosterone synthase deficiency. (15782303)
2005
30
Untreated chronic rhinosinusitis: a comparison of symptoms and mediator profiles. (15091235)
2004
31
Preclinical assessment of the proinflammatory potential of microbicide candidates. (16419269)
2004
32
What is your diagnosis? Cicatricial pemphigoid. (15293695)
2004
33
Crystallization and preliminary crystallographic studies of human coactosin-like protein (CLP). (15583396)
2004
34
Increased cerebral tissue oxygen tension after extensive hemodilution with a hemoglobin-based oxygen carrier. (15271734)
2004
35
Utility of immunohistochemistry in separating thymic neoplasms from germ cell tumors and metastatic lung cancer involving the anterior mediastinum. (12777991)
2003
36
Frosted branch angiitis associated with rapidly progressive glomerulonephritis. (12532498)
2002
37
Changes in mRNA and protein levels of proteoglycans of the anulus fibrosus and nucleus pulposus during intervertebral disc degeneration. (12394896)
2002
38
Chemotactic agents induce IL-6Ralpha shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-alpha-converting enzyme (TACE) type. (12355450)
2002
39
Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. (12226133)
2002
40
A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. (11572777)
2001
41
Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. (11336170)
2001
42
Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. (10742383)
2000
43
Blastomycosis in dogs: 115 cases (1980-1995). (9731260)
1998
44
No association of presenilin-1 intronic polymorphism and Alzheimer's disease in Australia. (9792621)
1998
45
Identification of an N-terminally truncated form of the chemokine RANTES and granulocyte-macrophage colony-stimulating factor as major eosinophil attractants released by cytokine-stimulated dermal fibroblasts. (8596049)
1996
46
Stimulus of the hypophyseal-adrenocortical axis with corticotropin releasing hormone (CRH) in acquired immunodeficiency syndrome. Evidence for activation of the immune-neuroendocrine system]. (8520591)
1995
47
Importance of peroxisomes in the formation of chenodeoxycholic acid in human liver. Metabolism of 3 alpha,7 alpha-dihydroxy-5 beta-cholestanoic acid in Zellweger syndrome. (2000261)
1991
48
Mycetoma or pseudomycetoma? A distinctive mycosis caused by dermatophytes. (6835354)
1983
49
A new glucose-6-phosphate dehydrogenase variant (G6PD Nagano) associated with congenital hemolytic anemia. (7166314)
1982
50
PROTHROMBIN DEFICIENCY AND THE EFFECTS OF VITAMIN K IN OBSTRUCTIVE JAUNDICE AND BILIARY FISTULA. (17857347)
1939

Variations for Migraine with Aura

About this section

Expression for genes affiliated with Migraine with Aura

About this section
Search GEO for disease gene expression data for Migraine with Aura.

GO Terms for genes affiliated with Migraine with Aura

About this section

Cellular components related to Migraine with Aura according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1intercalated discGO:001470410.3ATP1A2, SCN1A
2cytosolGO:00058297.4ATP1A2, EDNRA, HTR2A, HTR2C, INSR, NOTCH3

Biological processes related to Migraine with Aura according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of glycolytic processGO:004582110.2HTR2A, INSR
2artery smooth muscle contractionGO:001482410.1EDNRA, HTR2A
3regulation of blood pressureGO:000821710.0ATP1A2, EDNRA
4positive regulation of fat cell differentiationGO:004560010.0HTR2A, HTR2C
5vasoconstrictionGO:004231010.0EDNRA, SLC6A4
6visual learningGO:00085429.9ATP1A2, DRD2
7smooth muscle contractionGO:00069399.9EDNRA, HTR2A
8behavioral response to cocaineGO:00481489.7DRD2, HTR2A
9locomotory behaviorGO:00076269.7DRD2, HTR2C
10feeding behaviorGO:00076319.4DRD2, HTR2C
11response to amphetamineGO:00019759.4DBH, DRD2
12temperature homeostasisGO:00016599.4DRD2, HTR2A
13positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathwayGO:00514828.9DRD2, EDNRA, HTR2C
14memoryGO:00076138.9DBH, HTR2A, SLC6A4
15response to drugGO:00424938.6DRD2, HTR2A, HTR2C, MTHFR, SLC6A4
16G-protein coupled receptor signaling pathwayGO:00071868.3DRD2, EDNRA, HTR2A, HTR2C, INSR

Sources for Migraine with Aura

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet